Studies in the Area of Whooping Cough Reported from National Center for Immunization and Respiratory Diseases (Tetanus, Diphtheria, and Acellular Pertussis Vaccination Coverage Among Publicly Insured Pregnant Women, U.S., 2016-2019): Respiratory Tract Diseases and Conditions – Whooping Cough

2023 MAR 07 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Daily -- Investigators publish new report on whooping cough. According to news originating from Atlanta, Georgia, by NewsRx correspondents, research stated, “Vaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during pregnancy is highly effective against Bordetella pertussis in young infants. We aimed to evaluate the uptake of maternal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccination during the recommended gestation period of 27 through 36 weeks among women enrolled in a public medical insurance plan in the U.S.”

Our news correspondents obtained a quote from the research from National Center for Immunization and Respiratory Diseases: “In this analysis using Centers for Medicare and Medicaid Services insurance claims data, we identified women aged 15 through 49 years who delivered a live-born infant from 2016 through 2019. We identified claims for tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccination to calculate the proportion of women who were vaccinated during Weeks 27 through 36 of gestation in each calendar year. We also assessed the average annual maternal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis coverage by age group, race and ethnicity, U.S. Census region of residence, and plan type. Data were analyzed in 2021. Among 4,318,823 deliveries, the 4-year national average for tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccination was 26%, improving from 22% in 2016 to 31% in 2019 (p<0.001). Within subgroups, the lowest 4-year average coverage was among women aged 15 through 18 years (22%); Black, non-Hispanic (23%) and Hispanic women (24%); those residing in the South (18%); those enrolled in a Children’s Health Insurance Program plan (22%); and those covered by a fee-for-service plan (19%). Coverage increased across all subgroups from 2016 through 2019.”

According to the news reporters, the research concluded: “Although maternal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis coverage among publicly insured women in the U.S. increased from 2016 through 2019, it remained considerably lower than estimated national coverage, with notable differences by race and ethnicity.”

For more information on this research see: Tetanus, Diphtheria, and Acellular Pertussis Vaccination Coverage Among Publicly Insured Pregnant Women, U.S., 2016-2019. AJPM Focus, 2023,2(1):100060. The publisher for AJPM Focus is Elsevier.

A free version of this journal article is available at https://doi.org/10.1016/j.focus.2022.100060.

Our news editors report that more information may be obtained by contacting MS Tami H. Skoff, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States. Additional authors for this research include DVM Cheryl J. Isenhour, MPH Megan C. Lindley, PhD Fangjun Zhou, PhD Susan Hariri.

(Our reports deliver fact-based news of research and discoveries from around the world.)